LRG1 and familial pancreatic carcinoma: A vast amount of clinical reports observes increased s-LRG1 levels in the development of a variety of disorders such as inflammatory disorders (intestinal, renal, and respiratory systems), oncological pathology (e.g., colorectal cancer, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, lung cancer) and other chronic conditions (e.g., ulcerative colitis (UC), hydrocephalus, heart failure) [15,20,21,22,23,24,25,26,27,28,29].